Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-029682
Filing Date
2023-06-23
Accepted
2023-06-23 17:31:24
Documents
80
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A fulc-20201231.htm   iXBRL 10-K/A 2247715
2 EX-23.1 fulc-ex23_1.htm EX-23.1 11680
3 EX-31.1 fulc-ex31_1.htm EX-31.1 15845
4 EX-32.1 fulc-ex32_1.htm EX-32.1 8977
  Complete submission text file 0000950170-23-029682.txt   9714088

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20201231_pre.xml EX-101.PRE 419198
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20201231.xsd EX-101.SCH 64471
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fulc-20201231_def.xml EX-101.DEF 264139
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fulc-20201231_cal.xml EX-101.CAL 60907
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20201231_lab.xml EX-101.LAB 532446
74 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20201231_htm.xml XML 1923693
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38978 | Film No.: 231038837
SIC: 2834 Pharmaceutical Preparations